Genomic studies to unlock
the truth of active compounds
Genel provides pharmaceutical and cosmetic companies
with new services to enhance personalized care.
Genel proposes innovative approach:
using 3D cellular models and primary cells to highlight active ingredient effects on its gene target
combining bioscreening, new imaging system and bioinformatics to guarantee an effective, fast, reliable and ready-to-use result
The effects of omnipresent, ambivalent blue light
Cergy | 6-7 February 2019
Our CEO, Mme. Gaëlle SAINT-AURET will be talking at COMET 2019 about the various interesting effects we have unraveled about the blue light. Date : 6 February...
The Genel team will be attending the final conference of PERMIDES European project the next week!
Utrecht, The Netherlands | 12-13 June 2018
Our CEO, Gaëlle SAINT-AURET has been selected as speaker for our Innovative Screening Process for the Development of Personalized Anticancer Treatment. This...
GENEL présente à ADEBIOTECH 2018
Romainville-Grand Paris | 13-14 March 2018
Gaëlle Saint-Auret présente à ADEBIOTECH les 13 et 14 Mars prochain. Elle y discutera des outils d'intérêt pour l'étude de l'épigénétique.
Explore our most recent innovations : genERGY & genSPECTRA!
Grenoble | 15 April 2018
Discover new tests from GENEL: Compelling ways of analysing how mitochondria are boosted by an active ingredient and a unique method to study the effects of...
GENEL featured in the "Journal des Entreprises"
Grenoble | 9 June 2017
GENEL was cited in the "Journal des Entreprises" as a contributor of the biotech hub of grenoble for our research in the oncology department! Read the article...
Sharing our pride over what the Press has to say about us!
Grenoble | 10 April 2017
Annie Zylberberg from Présences Magazine has dedicated her piece to GENEL. Read the article below!
The key to performance
